

Sudhir S Kushwaha

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8082284/publications.pdf>

Version: 2024-02-01

27
papers

736
citations

687363

13
h-index

580821

25
g-index

27
all docs

27
docs citations

27
times ranked

912
citing authors

#	ARTICLE	IF	CITATIONS
1	Circulating progenitor cells are associated with plaque progression and long-term outcomes in heart transplant patients. <i>Cardiovascular Research</i> , 2022, 118, 1703-1712.	3.8	4
2	Sirolimus-Based Immunosuppression Is Associated with Decreased Incidence of Post-Transplant Lymphoproliferative Disorder after Heart Transplantation: A Double-Center Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 322.	2.4	5
3	Left Ventricular Hemodynamics and Relationship With Myocardial Recovery and Optimization in Patients Supported on CF-LVAD Therapy. <i>Journal of Cardiac Failure</i> , 2022, 28, 799-806.	1.7	6
4	Impact of Sirolimus as a Primary Immunosuppressant on Myocardial Fibrosis and Diastolic Function Following Heart Transplantation. <i>Journal of the American Heart Association</i> , 2021, 10, e018186.	3.7	11
5	Heart-After-Liver Transplantation Attenuates Rejection of Cardiac Allografts in Sensitized Patients. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1331-1340.	2.8	18
6	Malignancy among adult heart transplant recipients following patient-tailored dosing of anti-thymocyte globulin: a retrospective, nested case-control study of individualized dosing. <i>Transplant International</i> , 2021, 34, 2175-2183.	1.6	0
7	Incidence, Risk Factors, and Outcomes of Stroke Following Cardiac Transplantation. <i>Stroke</i> , 2021, 52, e720-e724.	2.0	7
8	Peripheral microvascular dysfunction is associated with plaque progression and adverse long-term outcomes in heart transplant patients. <i>ESC Heart Failure</i> , 2021, 8, 5266-5274.	3.1	5
9	Epidemiology, risk factors, and association of antifungal prophylaxis on early invasive fungal infection in heart transplant recipients. <i>Transplant Infectious Disease</i> , 2021, 23, e13714.	1.7	5
10	Physiology of Continuous-Flow Left Ventricular Assist Device Therapy. , 2021, 12, 2731-2767.		3
11	Diastolic Pulmonary Gradient as a Predictor of Right Ventricular Failure After Left Ventricular Assist Device Implantation. <i>Journal of the American Heart Association</i> , 2019, 8, e012073.	3.7	21
12	Incidence of Malignancies in Patients Treated With Sirolimus Following Heart Transplantation. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2676-2688.	2.8	38
13	Predictors and Outcomes of Renal Replacement Therapy After Left Ventricular Assist Device Implantation. <i>Mayo Clinic Proceedings</i> , 2019, 94, 1003-1014.	3.0	13
14	Outcomes After Cardiac Transplant for Wild Type Transthyretin Amyloidosis. <i>Transplantation</i> , 2018, 102, 1909-1913.	1.0	18
15	Long-Term Sirolimus for Primary Immunosuppression in Heart Transplant Recipients. <i>Journal of the American College of Cardiology</i> , 2018, 71, 636-650.	2.8	81
16	Pulmonary Pressure Assessment with the Total Artificial Heart. <i>ASAIO Journal</i> , 2018, 64, e34-e36.	1.6	2
17	International Analysis of LVAD Point-of-Care Versus Plasma INR: A Multicenter Study. <i>ASAIO Journal</i> , 2018, 64, e161-e165.	1.6	7
18	Importance of Routine Antihuman/Leukocyte Antibody Monitoring. <i>Circulation</i> , 2017, 136, 1350-1352.	1.6	12

#	ARTICLE	IF	CITATIONS
19	Postcardiotomy ECMO Support after High-risk Operations in Adult Congenital Heart Disease. <i>Congenital Heart Disease</i> , 2016, 11, 751-755.	0.2	30
20	Proximal thoracic aorta dimensions after continuous-flow left ventricular assist device implantation: Longitudinal changes and relation to aortic valve insufficiency. <i>Journal of Heart and Lung Transplantation</i> , 2016, 35, 423-432.	0.6	27
21	Clinical Implications of Intracoronary Imaging in Cardiac Allograft Vasculopathy. <i>Circulation: Cardiovascular Imaging</i> , 2015, 8, .	2.6	31
22	Intraoperative transesophageal echocardiographic guidance of total artificial heart implantation. <i>Journal of Heart and Lung Transplantation</i> , 2014, 33, 454-457.	0.6	2
23	Sirolimus as Primary Immunosuppression Attenuates Allograft Vasculopathy With Improved Late Survival and Decreased Cardiac Events After Cardiac Transplantation. <i>Circulation</i> , 2012, 125, 708-720.	1.6	105
24	No Major Neurologic Complications With Sirolimus Use in Heart Transplant Recipients. <i>Mayo Clinic Proceedings</i> , 2009, 84, 330-332.	3.0	24
25	Sirolimus affects cardiomyocytes to reduce left ventricular mass in heart transplant recipients. <i>European Heart Journal</i> , 2008, 29, 2742-2750.	2.2	54
26	Sirolimus As Primary Immunosuppressant Reduces Left Ventricular Mass and Improves Diastolic Function of the Cardiac Allograft. <i>Transplantation</i> , 2008, 86, 1395-1400.	1.0	45
27	Conversion to Sirolimus as Primary Immunosuppression Attenuates the Progression of Allograft Vasculopathy After Cardiac Transplantation. <i>Circulation</i> , 2007, 116, 2726-2733.	1.6	162